RICH INVESTING iDEAS

Thyrocare Technologies - Net loss of Rs. 18 Crore due to Covid-19 - Q4FY20 Thyrocare Technologies involves in provide Quality Diagnostic services in the Health care Segment in India. Established in the year 1996, the company conducts Clinical tests and laboratories.  Currently, the Market capitalization for Thyrocare is Rs. 2800 Crore. Book value comes at Rs. 75 per Share. It is virtually a Debt Free Company, where the Debt to Equity stands at 0.03. The Promoters holding is said to be around 66 Percent and there is no pledging on Promoters Share holding. The Interest coverage ratio (ICR) is also comes with sufficient numbers, around 120 Times. For the Last five years, the Sales growth is up 20 Percent and the Compounded profit growth were at 15 Percent. The Return on Equity (ROE) for the Thyrocare is 19 Percent over the past 5 years. In Q4FY20 - quarterly results, the Company reported its revenue of Rs. 94 Crore. The Expenditure was Rs. 64 Crore in the said period. Rs. 44.33 Crore has

Attractive Stock - Thyrocare Technologies Ltd - Fundamental Analysis The Company was started in the year 1996, making the business with the Preventive Care Laboratories. India's First laboratory automation was happened in Thyrocare. The Founder of this company, Mr. Velumani, Ex-Scientist of BARC, India. Currently, the Market Cap is around Rs. 3,300 Crore. The Book value is said to be Rs. 75 and the Current Market Price is trading at Rs. 612 per share, which is 8 Times more than the Book value. Promoters holding of 66 Percent and there is no pledging of shares by the Promoters side. Debt to Equity stands at 0.03, which is a healthy one for the Value Investors. The Interest Coverage Ratio(ICR) is at 140 Times. At the end of September 2019 quarter, the Reserves are Rs. 344 Crore in the Company Balance Sheet. For the FY2018-19, the Company's revenue was Rs. 370 Crore and the expenses are Rs. 222 Crore. The PBT was Rs. 147 Crore and the Net Profit was declared as Rs. 95 Crore. The E